Specialty drugs are playing a significant role in the increasing healthcare costs in the commercial market. In this third episode of a mini-series based on the 2022 Employee Health Trends report, Janet Young, M.D., Lead Clinical Scientist at Springbuk and co-author of the report, talks about which specialty drugs are driving the most cost and alternatives that benefits leaders can explore.

Discover why one condition has a relatively small percentage of people receiving a specialty drug, but that is still drive a large dollar value of spending, and hear which conditions our data scientists expect to drive growth of specialty drug use over the next couple of years.

Get tips for how employers can reduce costs on specialty drugs without reducing efficacy, including looking at where the drugs are administered. 

And learn the steps employers can take now to increase adoption of lower-cost alternative drugs and to ensure they are able to reap cost savings as new biosimilars come into the market over the next two to three years.

Listen as Janet provides recommendations for both employers and their employees.

• Connect with Janet on LinkedIn
• Get the complete 2022 Employee Health Trends report
• Connect with our co-hosts Jennifer Jones and Mike Pattengale 
• Subscribe so you don’t miss an episode: Apple Podcasts, Spotify, and other popular podcast players

Have feedback, questions, or suggestions for show ideas? Send them to us at [email protected].

Please rate and review us on your favorite podcast platform, and share it with your friends and colleagues. We appreciate you and thank you for listening!

Theme music: "Overboard" by Stay Outside